| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.70▲ | 3.85▼ | 3.85▼ | N/A | N/A |
| MA10 | 3.83▼ | 4.08▼ | 4.15▼ | N/A | N/A |
| MA20 | 4.16▼ | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | 30.556▼ | 32.070▼ | N/A | N/A | N/A |
| STOCH | 12.415▼ | N/A | N/A | N/A | N/A |
| WILL %R | -76.077▼ | -84.756▼ | N/A | N/A | N/A |
| CCI | -65.122 | -87.447 | N/A | N/A | N/A |
|
Tuesday, February 10, 2026 07:29 AM
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)PARAMUS, NJ, Feb.
|
|
Thursday, February 05, 2026 05:47 AM
Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, clinical development, finance, and corporate strategy, strengthening the ...
|
|
Tuesday, February 03, 2026 05:42 AM
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/02/26 | 3.925 | 4.08 | 3.53 | 3.78 | 172,100 |
| 10/02/26 | 5.90 | 5.90 | 4.50 | 4.50 | 281,065 |
| 09/02/26 | 7.79 | 8.1484 | 5.88 | 5.93 | 198,667 |
|
|
||||
|
|
||||
|
|